Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program

Area of Science:

• Pharmacology and Addiction Medicine
• Health Services Research
• Public Health Policy

Background:

• Buprenorphine is a key medication for substance use disorders in the US.
• Real-world treatment structures for buprenorphine are understudied.
• This study examines adherence to buprenorphine treatment guidelines using administrative data.

Purpose of the Study:

• To investigate adherence to buprenorphine treatment guidelines.
• To analyze service utilization in buprenorphine treatment episodes.
• To use Massachusetts Medicaid administrative data for real-world insights.

Main Methods:

• Identified buprenorphine treatment episodes via pharmacy claims (2009-present).
• Utilized service claims for physician, behavioral, and laboratory services.
• Compared observed service utilization with guideline recommendations across treatment phases.

Main Results:

• 3674 treatment episodes analyzed for 3005 beneficiaries.
• Low rates of testing for hepatitis C (23.2%), hepatitis B (19.6%), and HIV (13.7%).
• Adherence to physician and behavioral visit frequencies was below 50% in most phases, with significant proportions lacking these services.

Conclusions:

• Significant variability exists in buprenorphine treatment structure for Massachusetts Medicaid beneficiaries.
• Half or fewer episodes met recommended frequencies for physician and behavioral visits.
• Administrative data limitations necessitate further research to link service levels with positive outcomes.